Cytosine 5-hydroxymethylation regulates VHL gene expression in renal clear cell carcinoma
Metrics: PDF 1359 views | HTML 1911 views | ?
En-Guang Ma1,2,*, Yu-Feng Bai1,*, Wei Cao3, Yan Cao4, Yong-Gang Huang2, Huan-Chen Cheng5 and Rui-Hua An1
1The Department of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, China
2The Department of Urology Surgery, The First Hospital of Harbin, Harbin, China
3The Department of Urinary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
4The Department of Urology, Harbin Medical University Cancer Hospital, Harbin, China
5Institute of Harbin Hematology & Oncology, The First Hospital of Harbin, Harbin, China
*These authors have contributed equally to this work
Rui-Hua An, email: [email protected]
Keywords: DNA methylation, hydroxymethylation, VHL, renal clear cell carcinoma
Received: February 13, 2017 Accepted: May 23, 2017 Published: July 07, 2017
Cytosine5-hyxymethylation (5hmC)which is a new epigenetic modification form plays important roles in the development and progression of tumors. In the present study, we observed that levels of 5hmC in the promoter region of Von Hippel-Lindau (VHL) were lower in 97 samples of renal clear cell carcinoma tissue than in matched adjacent benign tissues. Moreover, when the cancer tissue samples were divided based on pathological staging, VHL expression and the level of 5hmC in the VHL promoter were both lower in pathological grade III tumors than in grades I or II. Correspondingly, expression of TET1, which catalyzes the formation of 5hmC, was also lower in grade III renal clear cell carcinomas than in grade I or II disease. These findings suggest the 5hmC level on VHL is a key determinant of the gene’s expression and may participate in the occurrence and development of renal clear cell carcinoma. Thus the 5hmC level may be a useful indicator for early diagnosis and appropriate treatment of renal clear cell carcinoma.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.